Clinical Data Inc

Clinical Data — Technical Presentation (May 2010)

10 slides from Clinical Data's technical presentation, May 25, 2010

  1. Slide 1: A 1-Year Open-Label Study Assessing Safety and Tolerability of Vilazodone in MDD

    Exhibit 99.3 Poster NR4-22 A 1-Year Open-Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder Donald S. Robinson, MD,1 Daniel K. Kajdasz, PhD,2 Susan Gallipoli, RN,2 Heidi Whalen, MHS,2 Art Wamil, MD, PhD,2 Carol R. Reed, MD2 1Worldwide Drug Deve

  2. Slide 2: Presented at the 163rd Annual Meeting of the American Psychiatric Association

    • The protocol was approved by the institutional review board of each center Presented at the 163rd Annual Meeting of the American Supported by PGxHealth, LLC Psychiatric Association, May 22-26, 2010, New Orleans, Louisiana

  3. Slide 3: Study Population and Study Design

    Study Population • Selected inclusion criteria — Male and female patients; 18 to 70 years of age — Diagnosis of MDD according to the DSM-IV-TR, as confirmed by Mini-International Neuropsychiatric Interview — 17-item Hamilton Depression Scale (HAM-D-17) score of ≥18 at screening and baseline visits •

  4. Slide 4: Statistical Analysis

    • AEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA, V 11.1), and were summarized by System Organ Class and Preferred Term • AEs were summarized by number and percentage of patients experiencing each AE Effectiveness • Effectiveness evaluations were based on the ef

  5. Slide 5: Results

    Results • 616 patients were enrolled in the study, and 254 patients (41.2%) completed the study; 313 (51%) completed at least 6 months of the study (Figure 1) Figure 1. Subject disposition. a n (%) of enrolled population. • Baseline demographic and disease characteristics are presented in Table 1 •

  6. Slide 6: Baseline Demographic and Disease Characteristics (continued)

    44 (18-70) Duration of current MDD episode, n (%) 1-6 mo 215 (35.9) >6-12 mo 172 (28.7) >12 mo 212 (35.4) Severity of current episode,a n (%) Mild 11 (1.8) Moderate 469 (78.3) Severe 119 (19.9) a DSM-IV-TR criteria of MDD severity: mild = 5 or 6 depressive symptoms; severe without psychotic features

  7. Slide 7: Safety and Tolerability Results

    Safety and Tolerability Results • Treatment-emergent AEs (TEAEs) led to discontinuation in 124 of 599 patients (20.7%); specific TEAEs leading to discontinuation in ≥1% of patients were nausea (1.3%), diarrhea (1.2%), and anxiety (1.0%) • Most TEAEs were rated mild or moderate in intensity (95.9%);

  8. Slide 8: Vital Signs, Laboratory, ECG and Sexual Function Results

    Week 52 254 1.71 (5.90) SBP, systolic blood pressure; DBP, diastolic blood pressure; bpm, beats per minute. • Mean changes from baseline in hematology, blood chemistry, and urinalysis values showed no clinically important trends • Treatment-emergent elevations in LFTs to ≥3.0 × the upper limit of th

  9. Slide 9: Effectiveness Results and Conclusions

    Effectiveness Results • Effectiveness measures showed improvement over 52 weeks of treatment — Mean MADRS score was 29.9 at baseline and 7.1 at week 52 (Figure 2) — Mean CGI-S score was 4.3 at baseline and 1.7 at week 52, representing an overall change of -2.6 — Mean CGI-I score was 3.5 at week 1 an

  10. Slide 10: References

    2. Geddes JR et al. Lancet. 2003;361:653-661. 3. US Food and Drug Administration. Guidance for Industry ICH-E1A. 1995. 4. Hughes A et al. Eur J Pharmacol. 2005;510:49-57. 5. Dawson L et al. CNS Neurosci Ther. 2009;15:107-117. 6. Rickels K et al. J Clin Psychiatry. 2009;70:326-333.

Clinical Data — Technical Presentation (May 2010) on 6ix